Compounds > l 685434
Page last updated: 2024-08-01 19:12:34

l 685434

Description

L 685434: structure given in first source; a pseudopeptide with activity against HIV protease [MeSH]

Cross-References

ID SourceID
PubMed CID5464035
CHEMBL ID296115
CHEMBL ID308780
SCHEMBL ID6362854
MeSH IDM0201491

Synonyms (21)

Synonym
chembl296115 ,
tert-butyl n-[(2s,3s,5r)-5-benzyl-3-hydroxy-5-{[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]carbamoyl}-1-phenylpentan-2-yl]carbamate
urethane deriv. 1
bdbm1030
126456-36-8
carbamic acid, [(1s,2s,4r)-5-[[(1s,2r)-2,3-dihydro-2-hydroxy-1h-inden-1-yl]amino]-2-hydroxy-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester
l-685434
tert-butyl n-[(1s,2s,4r)-1,4-dibenzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxyindan-1-yl]amino]-5-oxo-pentyl]carbamate
l-685,434
l 685434
tert-butyl n-[(2s,3s,5r)-5-benzyl-3-hydroxy-6-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-6-oxo-1-phenylhexan-2-yl]carbamate
[1-benzyl-2-hydroxy-4-(2-hydroxy-indan-1-ylcarbamoyl)-5-phenyl-pentyl]-carbamic acid tert-butyl ester
chembl308780
bdbm50009261
(1s-(1alpha(1r*,2r*,4s*),2alpha))-1,1-dimethylethyl (5-((2,3-dihydro-2-hydroxy-1h-inden-1-yl)amino)-2-hydroxy-5-oxo-1,4-bis(phenylmethyl)pentyl)carbamate
carbamic acid, (5-((2,3-dihydro-2-hydroxy-1h-inden-1-yl)amino)-2-hydroxy-5-oxo-1,4-bis(phenylmethyl)pentyl)-, 1,1-dimethylethyl ester, (1s-(1alpha(1r*,2r*,4s*),2alpha))-
carbamic acid, ((1s,2s,4r)-5-(((1s,2r)-2,3-dihydro-2-hydroxy-1h-inden-1-yl)amino)-2-hydroxy-5-oxo-1,4-bis(phenylmethyl)pentyl)-, 1,1-dimethylethyl ester
SCHEMBL6362854
2-benzyl-5-{[tert-butoxy(hydroxy)methylidene]amino}-4-hydroxy-n-(2-hydroxy-2,3-dihydro-1h-inden-1-yl)-6-phenylhexanimidic acid
DTXSID10925558
AKOS040752318

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)IC500.0003AID1795249; AID1795278; AID1795281; AID1795289
Protease Human immunodeficiency virus 1IC500.0003AID160770; AID161379; AID161728; AID162026; AID162180; AID162194; AID162206; AID162513; AID163476

Other Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Protease Human immunodeficiency virus 1IC950.4000AID161883; AID163473

Bioassays (22)

Assay IDTitleYearJournalArticle
AID161728Inhibition of HIV-1 protease1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
ISSN: 0022-2623		HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity.
AID162194In vitro inhibition of HIV-1 protease1995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
ISSN: 0022-2623		A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site.
AID81070Anti-viral activity was determined2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
ISSN: 0022-2623		Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
AID160770Inhibitory activity against HIV-1 protease.1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
ISSN: 0022-2623		Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.
AID162513The compound was tested for its affinity against HIV-1 protease1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
ISSN: 0022-2623		HIV protease: a novel chemotherapeutic target for AIDS.
AID162206Inhibitory activity against HIV-1 protease was determined2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
ISSN: 0022-2623		Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
AID161883Cellular antiviral activity against HIV-1 Protease1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
ISSN: 0022-2623		An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
AID226650Ratio of inhibitory activity on HIV-1 protease (IC50) to antiviral activity against HIV-1 in human H9 T-lymphoid cell-ELISA assay(CIC)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
ISSN: 0022-2623		Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID163476Inhibition of HIV-1 protease1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
ISSN: 0022-2623		3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors.
AID161379Inhibition of HIV protease1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
ISSN: 0022-2623		Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors.
AID79236Inhibitory activity against HIV-1IIIb in H-9 cells using immunofluorescence1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
ISSN: 0022-2623		HIV protease: a novel chemotherapeutic target for AIDS.
AID162026Inhibition of HIV-1 protease1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
ISSN: 0022-2623		An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
AID227879Ratio (CIC95/IC50) of cellular antiviral activity over the isolated enzyme potency2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
ISSN: 0022-2623		Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
AID232360Ratio of CIC95 to IC50 values1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
ISSN: 0022-2623		An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
AID221810In vitro anti viral activity against HIV-1 in human H9 T-lymphoid cell culture by fixed cell immunofluorescence assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
ISSN: 0022-2623		Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID162180In vitro enzyme inhibitory activity against HIV-1 protease.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
ISSN: 0022-2623		Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID221809Ex vivo antiviral activity in H9 T-lymphoid cells infected with HIV-1(IIIB).1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
ISSN: 0022-2623		HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity.
AID163473Inhibitory concentration was evaluated to inhibit the 95% of HIV-1 protease1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
ISSN: 0022-2623		3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors.
AID1795289Protease Inhibition Assay from Article 10.1021/jm00088a004: \\HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity.\\1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
ISSN: 0022-2623		HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity.
AID1795249Protease Inhibition Assay from Article 10.1021/jm00054a015: \\3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors.\\1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
ISSN: 0022-2623		3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors.
AID1795281Protease Inhibition Assay from Article 10.1021/jm00088a003: \\Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.\\1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
ISSN: 0022-2623		Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID1795278Protease Inhibition Assay from Article 10.1021/jm00107a051: \\Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors.\\1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
ISSN: 0022-2623		Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors.

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (88.89)18.2507
2000's1 (11.11)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
haloperidol
1
aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist		1991199133.0low001000
zidovudine
1
azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor		1992199232.0low001000
a 74704
1
1991199133.0medium001000
saquinavir
2
L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor		1995199827.5medium002000
cerulenin
1
epoxide;
monocarboxylic acid amide		antifungal agent;
antiinfective agent;
antilipemic drug;
antimetabolite;
antimicrobial agent;
fatty acid synthesis inhibitor		1991199133.0low001000
indinavir sulfate
2
dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor1997200324.0medium001100
l 689502
1
1992199232.0medium001000
l 682679
3
1992200326.7high002100
pepstatin
1
pentapeptide;
secondary carboxamide		bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor		1991199133.0low001000
u 75875
1
1991199133.0medium001000
streptomyces pepsin inhibitor
1
1991199133.0medium001000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
pyrroles
1
pyrrole;
secondary amine		1997199727.0low001000
indinavir sulfate
1
dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor1997199727.0low001000
l 682679
1
1992199232.0high001000
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Acquired Immune Deficiency Syndrome0
1
1991199133.0high001000
Acquired Immunodeficiency Syndrome0
1
1991199133.0high001000

Bioavailability (1)

ArticleYear
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
Journal of medicinal chemistry, , May-08, Volume: 46, Issue:10		2003